Localization and disposition of a non-peptide angiotensin II type 1 receptor antagonist, and its glucuronide metabolite, in rat.

1. The disposition of radioactivity of a non-peptide angiotensin II type 1 receptor antagonist (E4177) has been studied in groups of male rats after a single oral 1 mg/kg dose of 14C-E4177 was administered by gavage. We have also used light-microscopic autoradiography to investigate the localization of radioactivity in the target tissues for this angiotensin II receptor antagonist. 2. The radioactivity was absorbed quickly, and the maximum blood levels (Cmax) were reached at 0.38 +/- 0.14 h after dosing. The concentrations then declined bi-exponentially with a mean apparent half-life for the first phase (t1/2 alpha) of 0.46 +/- 0.07 h and a terminal half-life (t1/2 beta) of 6.22 +/- 1.08 h. By 24 h, the levels had decreased to 2.7 +/- 1.5% Cmax. The blood levels radioactivity at 48 h after administration were below the limit of quantification. 3. Radioactivity was distributed throughout the body at 15 min after administration. Tissues in which radioactivity was present at higher levels than in plasma were the liver and kidney. Radioactivity was rapidly eliminated from the tissues and was not retained in any individual organ. 4. The major route of excretion was via the bile. Since > 90% of the administered radioactivity was recovered by 24 h after administration, the excretion was relatively rapid. The major metabolite in bile was a glucuronide of E4177 biphenylcarboxylic acid (E4177-Glu). 5. Light-microscopic autoradiographic observations revealed a strong localization of radioactivity throughout the surface cells of the adrenal glomerulosa, the blood vessels in kidney and the surface of the aortic smooth muscle cells, which are all rich in angiotensin II type 1 (AT1) receptors.

[1]  M. Kakiki,et al.  Localization of a novel non-peptide angiotensin II type 1 receptor antagonist, E4177, in rat adrenal glomerulosa. , 1996, Biological & pharmaceutical bulletin.

[2]  H. Sasamura,et al.  Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors , 1995, The Journal of biological chemistry.

[3]  T. Rogers,et al.  Angiotensin II stimulates the release of phospholipid-derived second messengers through multiple receptor subtypes in heart cells. , 1994, The Journal of biological chemistry.

[4]  R D Smith,et al.  Angiotensin II receptor subtypes. , 1992, American journal of hypertension.

[5]  D. Healy,et al.  Characterization of an angiotensin type-1 receptor partial cDNA from rat kidney: evidence for a novel AT1B receptor subtype. , 1992, Biochemical and biophysical research communications.

[6]  K. Catt,et al.  Cloning and expression of a novel angiotensin II receptor subtype. , 1992, The Journal of biological chemistry.

[7]  M. Schambelan,et al.  Distribution of angiotensin II receptor subtypes in rat and human kidney. , 1992, The American journal of physiology.

[8]  R. Alexander,et al.  Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor , 1991, Nature.

[9]  P. Timmermans,et al.  Identification of angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.

[10]  S. Whitebread,et al.  Preliminary biochemical characterization of two angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.

[11]  M. Miyazaki,et al.  Nephrectomy and a newly identified binding site for angiotensin II in the rat adrenal cortex. , 1992, Life sciences.

[12]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. , 1990, American journal of hypertension.